NASDAQ:CLGN - Nasdaq - IL0004960188 - Common Stock - Currency: USD
Taking everything into account, CLGN scores 3 out of 10 in our fundamental rating. CLGN was compared to 555 industry peers in the Biotechnology industry. While CLGN seems to be doing ok healthwise, there are quite some concerns on its profitability. CLGN is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.58% | ||
ROE | -111.85% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 48.71% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -9.36 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 4.48 | ||
Quick Ratio | 4.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 45.1 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.38
+0 (+0.36%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 45.1 | ||
P/S | 6.39 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.27 | ||
P/tB | 1.29 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.58% | ||
ROE | -111.85% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 48.71% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 40.92% | ||
Cap/Sales | 16.59% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 4.48 | ||
Quick Ratio | 4.23 | ||
Altman-Z | -9.36 |